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Introduction: The emergence of treatments for non-small cell lung
carcinoma (NSCLC) with differential efficacy and toxicity between
subtypes has highlighted the importance of specific pathologic
NSCLC subtyping. Most NSCLCs are inoperable, and pathologic
diagnosis is made only on small tissue samples that are prone to
diagnostic inaccuracy. In a substantial proportion of cases, standard
morphology cannot specifically subtype the tumor, necessitating a
diagnosis of NSCLC-not otherwise specified (NOS). Histochemical
staining for mucin and immunohistochemical (IHC) identification of
NSCLC subtype-associated markers could help predict the final
subtype of resected NSCLCs diagnosed as NSCLC-NOS on preop-
erative bronchial biopsy samples.
Methods: Paraffin sections of 44 bronchial biopsy samples diagnosed
as NSCLC-NOS were stained for mucin (Alcian blue/periodic acid
Schiff) and thyroid transcription factor 1 by IHC–(markers of adeno-
carcinoma), and for S100A7, cytokeratin 5/6, high molecular weight
cytokeratins, and p63 proteins–markers of squamous cell carcinoma. A
predictive staining panel was derived from statistical analysis after
comparing staining profiles with the final postsurgical NSCLC subtype.
This panel was prospectively applied to 82 small biopsy samples
containing NSCLC.
Results: True NSCLC subtype of undifferentiated NSCLC samples
was best predicted using Alcian blue/periodic acid Schiff plus p63
and thyroid transcription factor 1 IHC, allowing specific subtyping
in 73% of NSCLC-NOS cases with 86% accuracy. When applied
prospectively, this staining panel showed 100% concordance with
specific NSCLC morphologic subtyping in small biopsies.
Conclusion: This approach can facilitate treatment selection by
accurately predicting the subtype in undifferentiated NSCLC biop-
sies, reducing to 7% the proportion of cases without a definite or
probable histologic subtype.
Key Words: Non-small cell lung carcinoma, NSCLC-NOS, Undif-
ferentiated carcinoma, Bronchial biopsy diagnosis, NSCLC subtype,
Immunohistochemistry, TTF1, p63, Predictive value.
(J Thorac Oncol. 2010;5: 442–447)
Until recently, the histologic subtyping of non-small celllung carcinoma (NSCLC) was not clinically or therapeu-
tically important, because of a lack of differential treatment
options for NSCLC subtypes. The relevant distinction that
determine treatment choice had always been between small
cell and NSCLC, a differential diagnosis that pathologists are
able to make consistently and accurately.1–3 The emergence
of treatments with differential activity (e.g., pemetrexed) or
limited indication (e.g., bevacizumab) in subtypes of NSCLC
has placed a new emphasis on the importance of accurate
subtyping.4,5
In practice, resection rates for lung cancer are 10 to
15%. Thus, relatively few cases undergo complete histologic
examination, and the subsequent application of the World
Health Organization (WHO) classification of primary lung
carcinoma is limited.6 In consequence, the majority of pa-
tients are managed on the basis of a diagnosis made on a
single small tumor biopsy or even a cytologic sample. Many
NSCLC are heterogeneous, although not in terms of mixed
differentiation, they certainly show areas of undifferentiated
tumor that lack the light-microscopic features of differentia-
tion visible in other parts of the lesion. This combination of
small diagnostic sample size and tumor heterogeneity results
in many diagnostic samples being unrepresentative of the true
tumor histology and explains the consequent reported lack of
consistency and accuracy in subtyping NSCLCs in this con-
text.7–12 In addition, this is also why large cell carcinoma, as
defined in the WHO classification, cannot be accurately
diagnosed in small biopsy or cytology material. Reported
figures for diagnostic accuracy of large cell carcinoma are
50% or less, whereas for either squamous cell or adenocar-
cinoma, it is higher, ranging from 65 to 90%. When undif-
ferentiated NSCLC is present in such samples, a diagnosis of
non-small cell carcinoma, not otherwise specified (NSCLC-
NOS) is recommended.8,13 Some studies have found that this
diagnosis accounts for 25% of non-small cell carcinoma
diagnoses in small biopsy samples and 45% of cytology
samples.9
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When used appropriately, immunohistochemical (IHC)
staining can allow tumor subtype to be inferred when histo-
logic morphology is nonspecific. Antibodies to cytokeratins
5/6 (CK5/6) and high molecular weight cytokeratins (HM-
WCK [CK 1, 5, 8, and 14]-34E12) and to S100A7 and p63
proteins have been used to infer squamous phenotypes.14–24
Mucin is a useful diagnostic feature of many adenocarcino-
mas and 70 to 85% of lung adenocarcinomas express thyroid
transcription factor (TTF) 1.25–27 In this study, we evaluate
the ability of these IHC markers and mucin staining to predict
the likely NSCLC subtype in cases where the bronchial
biopsy diagnosis was NSCLC-NOS and the tumor was sub-
sequently resected and definitively categorized.
MATERIALS AND METHODS
Fifty cases of surgically resected lung cancer, preoper-
atively diagnosed as NSCLC-NOS on bronchial biopsy sam-
ples, were selected from the case files of the Department of
Pathology at Aberdeen Royal Infirmary. Final diagnoses and
histologic NSCLC subtypes were recorded from the depart-
mental case records for each subsequent surgical resection
specimen, with resort to slide review where necessary (Table 1).
All diagnostic materials (slides and tissue blocks) were
readily available. Four cases had insufficient tissue remaining
in the original bronchial biopsy paraffin-embedded tissue
block to allow inclusion in this study.
Forty-six cases had 4-m thick sections cut and
mounted on charged Chem Mate slides (Dako, Ely, UK).
Sections from each case were stained for mucin (Alcian
blue/periodic acid Schiff [AB/PAS]-without nuclear counter-
stain) and with a panel of antibodies against S100A7 (1:100;
Novocastra, Peterborough, UK), p63 (1:50; Novocastra), CK
5/6 (1:200; Zymed, Paisley, UK), 34E12-HMWCK (1:100;
Dako), and TTF1 (1:50; Dako) using standard immunohisto-
chemistry methodology (heat antigen retrieval, DAKO
Benchmark XT autostainer, and Ultraview visualization
[Dako]). Of the 46 cases, two further cases were excluded as
the relevant tumor tissue cut out on further sectioning; 44
cases had all immunostains and mucin histochemistry
performed.
Any intracytoplasmic mucin droplet staining with
AB/PAS in tumor cells was considered positive. The IHC
slides were double scored by two of the authors (P.S.L. and
K.M.K.). Intensity of staining was graded into four semi-
quantitative categories: (a) absent score 0, (b) light score
1, (c) intermediate  score 2, and (d) strong  score 3.
Similarly, the proportion of cells staining was categorized as
follows: (a) none  score 0, (b) 1 to 10%  score 1, (c) 10
to 50%  score 2, and (d) 50%  score 3.
Neural nets were used to optimize the categorization of
IHC scores into positive or negative, to provide the best
predictive cutoff values for the semiquantitative scores ob-
tained from each antibody.28 The raw scores for each marker
for each biopsy specimen were fed into simple neural nets
comprising three nonlinear perceptrons (neurones), arranged
into two layers. Given the limited data set, the nets were
trained using all of the scored biopsy specimens. Analysis of
net outputs for each of the observed staining patterns for each
marker divided those patterns into areas that were nonpredic-
tive (negative) or predictive (positive) for each tumor sub-
type. In transition areas between nonpredictive and predictive
staining patterns, where no input scores were available from
our dataset, the output was recorded as no data. Positive and
negative predictive values, sensitivity, and specificity were
calculated for each marker and for various combinations of
markers to predict tumor histotype.
After establishing a set of predictive tests, based on the
scoring system described above and the predictive score
thresholds subsequently defined by the retrospective series of
44 cases, we applied this diagnostic panel of combined
AB/PAS plus TTF1, p63, and CK5/6 IHC prospectively in 82
small biopsy samples of lung cancer from various sites (Table 2).
Forty-one of these cases were specifically classifiable on the
hematoxylin and eosin (HE) stain as either squamous cell or
adenocarcinoma—Table 2; six tumors were subsequently
resected. Of the remaining 41 cases, each were considered
NSCLC-NOS on the HE stained sections. Only two of these
cases were resected and definitively histotyped. This work
was performed with the appropriate ethical approval from
Grampian research ethics committee.
TABLE 1. Breakdown of Final Resection and IHC-Predicted




Squamous cell carcinoma 23a 22 0 1
Adenocarcinoma 11b 0 8 3
Large cell carcinoma 8c 4 1 3
Adenosquamous carcinoma 2 1 1 0
Null refers to a nonpredictive immunophenotype (see text).
a Two of these cases were basaloid variant, and one showed sarcomatoid carcinoma.
b One was combined with large cell neuroendocrine carcinoma.
c Two were basaloid variants.
IHC, immunohistochemical.
TABLE 2. Summary of Cases Prospectively Stained Using the
Diagnostic Panel Determined by the Retrospective Analysis
Small Biopsy Type No. Cases (Total  82)
Bronchial biopsy 65
Transthoracic lung core biopsy 12
Liver biopsy 3
Lymph node biopsy 2
Pre Panel HE Diagnosis on
Prospective Cases
No. Cases
(Total  82) Panel Prediction
Squamous cell carcinoma 25 All squamous cell carcinoma
Adenocarcinoma 16 All adenocarcinoma
NSCLC-NOS 41 19 Squamous cell carcinoma
11 Adenocarcinoma
11 Not predictivea
a These cases had null immunohistochemical phenotypes. One case was predicted
as both squamous and adenocarcinoma.
HE, hematoxylin and eosin stain; NSCLC-NOS, non-small cell lung carcinoma-not
otherwise specified.
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RESULTS
After attrition because of inadequate biopsy material,
44 resection specimens initially diagnosed as NSCLC-NOS
on small sample biopsy were included in this study. Table 1
summarizes the distribution of the final diagnosis after resec-
tion. Squamous cell carcinoma was the dominant type, ac-
counting for just more than half of the cases; one quarter of
cases were adenocarcinoma.
All of the markers showed variability in staining with
respect to intensity and proportion of tumor cells stained.
Overall, different tumor types showed different, but overlap-
ping, staining profiles. Figure 1 shows the pairwise interpre-
tation of staining scores for each marker. Any staining for
S100A7 was considered predictive. Higher levels of CK5/6
and p63 staining were predictive; weak staining of 10% of
the tumor cells was not predictive. In general, for TTF1, p63,
CK5/6, and HMWCK, staining was either nonexistent/weak
or abundant and strong. Tumors showing intermediate levels
of staining were relatively less well represented in our data
set. Thus, the transition areas between staining scores inter-
preted as negative and positive are less reliable than areas
more deeply set within the negative and positive zones.
Moreover, for HMWCK and TTF1, certain score combina-
tions were not encountered and could not be extrapolated
from surrounding scores by the nets. These areas were re-
corded as no data (Figure 1).
The ability, in numerical terms, of the four selected
markers, S100A7, p63, CK5/6,and HMWCK, to correctly
predict a squamous histotype are summarized in Table 3. The
marker p63 showed the best sensitivity, whereas CK5/6
showed the best specificity. These scores for individual mark-
ers could not be improved by considering combination scores
for more than one marker. Any combination of TTF1 and
mucin positivity yielded the best figures for predicting an
adenocarcinoma in the resection specimen (Table 3). To
predict a nonsquamous histotype, the best results were ob-
tained using a negative (nonpredictive—Figure 1) p63 stain
and/or a positive AB/PAS stain.
Staining of preoperative samples from true large cell
carcinomas (8 cases) showed a squamous profile in four cases,
an adenocarcinoma profile in one case, and in three cases, a
profile of low-level staining suggestive of neither squamous
nor adenocarcinoma (a nonpredictive null immunophenotype;
Table 1). After ignoring those cases diagnosed as adenosqua-
mous carcinoma at resection, of 23 definitive squamous
cases, 22 showed a squamous immunophenotype at biopsy
and one showed a null immunophenotype. Of 11 definitive
adenocarcinomas, eight showed a consistent adenocarcinoma
immunophenotype on biopsy and three showed a null immu-
nophenotype. These data mean that of the seven cases show-
ing a null immunophenotype at biopsy, one was squamous,
three were adenocarcinomas, and three were true large cell
carcinoma at resection.
From the above data, a diagnostic panel of combined
AB/PAS for mucin plus IHC for TTF1, p63, and CK5/6 was
determined. Although the statistical data suggested that the
addition of another squamous marker in addition to p63
would not improve the efficacy of prediction of NSCLC
histotype, it was recognized that in cases where the p63 score
falls into the transitional area between very weak and very
strong staining—i.e., when scores of 1  2 (intensity 
proportion), 22, or 21 were allocated—then the predictive
value is less certain, and the 50 addition of CK5/6 would
seem prudent.
FIGURE 1. Summary diagrams of immunohistochemical
staining for each of the markers. The shades indicate
whether each possible combination of intensity and distribu-
tion score were considered positive (predictive of histotype)
or negative (not predictive), as determined by statistical
analysis (see Materials and Methods).










Markers to correctly predict
a squamous histotype
S100A7 36 74 64 47
p63 92 74 82 88
CK5/6 84 79 84 79
HMWK 88 74 81 82
p63 or CK5/6 92 74 82 88
Markers to correctly predict
an adenocarcinoma histotype
AB/PAS 23 100 100 76
TTF1 54 97 88 83
TTF1 or AB/PAS 69 97 90 88
Markers to correctly predict
a non-squamous histotype
p63 () and AB/PAS () 78 92 88 85
PPV, positive predictive values; NPV, negative predictive values; CK5/6, cytoker-
atins 5/6; HMWK, high molecular weight cytokeratins; AB/PAS, Alcian blue/periodic
acid Schiff; TTF1, thyroid transcription factor 1.
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Eighty-two small biopsy samples were prospectively
stained using this panel. Half of these cases could be specif-
ically subtyped on HE histology alone into squamous cell or
adenocarcinoma (Table 2). All of these cases showed a
predictive staining profile entirely commensurate with the HE
diagnosis. Six of these cases were subsequently resected, all
of which showed the expected histotype—four squamous cell
and two adenocarcinomas. Of the remaining 41 cases classi-
fied as NSCLC-NOS, the staining panel predicted squamous
cell carcinoma in 19 cases, adenocarcinoma in 11 cases,
leaving 11 cases with a null phenotype. Only two of these 41
NSCLC-NOS cases were subsequently resected. In one case,
the squamous nature of the tumor was correctly predicted
from the small biopsy using the panel. In the other case, the
small sample was reported as being NSCLC-NOS after the
panel, despite the p63 score being (2  1), and, thus,
predictive of a squamous phenotype. This was because the
score lay in the transition area between very weak and very
strong staining and the CK5/6 score was negative. Both TTF1
and mucin were negative in this second case. At resection,
this latter case was definitively categorized as a poorly
differentiated adenocarcinoma.
DISCUSSION
This study has focused primarily on the performance of
putative markers of squamous cell (p63, CK5/6, HMWCK,
and S100A7) and adenocarcinoma (mucin stain and TTF1) to
predict the likely histologic subtype of a NSCLC, when
applied to a biopsy sample that shows only undifferentiated
NSCLC. This study is timely given the rise in prescribing
licenses and treatment response and toxicity effects predi-
cated on tumor histology.
The data presented indicated that the best positive
predictive marker of squamous histology was p63 alone.
However, in situations of moderate p63 staining, CK5/6
could be added. HMWCK and S100A7 were somewhat
inferior as markers of squamous histotype. Combining an
AB/PAS mucin stain with TTF1 IHC provided moderate
sensitivity but excellent specificity for predicting an adeno-
carcinoma histotype.
Most of the published literature on this subject de-
scribes the expression of markers in morphologically diag-
nosable squamous cell or adenocarcinomas obtained from
surgically resected specimens, autopsy cases, bronchial bi-
opsy samples, or cytologic material.16–20,23–25,29 These studies
report between 75 and 100% of squamous cell carcinomas as
positive for p63; most series report positive rates of 90%.
Few studies provide criteria for a positive stain, although one
stipulated that10% of cells should express p63 for a case to
be considered positive.20 Zhang et al.19 found all squamous
cell carcinomas expressed HMWCK, whereas Camilo et al.20
found only 56.2% of such tumors were positive for CK5/6.
Although S100A7 has been suggested as a marker confined to
squamous and large cell carcinomas,23 our data suggest that it
is neither sensitive nor specific enough to be of diagnostic
value in the setting tested. Our anecdotal experience with
S100A7 (data not shown) is that staining in squamous cell
carcinomas is very patchy and concentrates on well-differen-
tiated areas, readily recognizable on the HE stained sections.
Kargi et al.21 found that p63 and CK5/6 differentially
stained easily recognizable adenocarcinomas and squamous
cell carcinomas with 89% specificity and 79% sensitivity.
Kaufmann et al.14 also found that p63 and CK5/6 were
superior to either marker alone in HE-diagnosable, although
poorly differentiated, squamous cell carcinomas. Further-
more, they reported that if a positive result required50% of
cells to be stained, specificity rose to 99%, but sensitivity fell
to 66%.
Many studies have demonstrated TTF1 expression in
70 to 85% of resected lung adenocarcinoma.25–27,30 In the
context of small biopsy or cytology samples, TTF1 stains
anywhere between 60 and 92% of morphologically diagnos-
able adenocarcinomas. The variations are probably a function
of the sample types predominant in the study29,31–33; more
transthoracic aspiration or core samples and fewer bronchial
samples will bias results toward terminal respiratory unit-type
adenocarcinomas and raise the TTF1 prevalence.26 Stainable
mucin is one of the defining characteristics of pulmonary
adenocarcinoma, although not all cases are positive,34 and
expression can be very patchy. There is limited published
data, but it is the authors’ impression that the AB/PAS stain
will retain a high probability of staining central, bronchial-
type, or poorly differentiated adenocarcinomas that are more
likely to be TTF1 negative.27 Kaufmann and Dietel25 found
TTF1 positivity in 75% of nonmucinous but only 10% of
mucinous adenocarcinomas, hence, the value of using both
TTF1 and AB/PAS in the diagnostic panel.
The studies outlined above examined morphologically
diagnosable squamous cell and adenocarcinomas. Besides our
own studies, there are very few other studies examining the
ability of ancillary techniques to predict the true NSCLC sub-
type of undifferentiated biopsy samples. Rossi et al.33 studied
cases diagnosed as large cell carcinoma on bronchial biopsy and
found that TTF1 or CK 7 as markers of adenocarcinoma and
HMWCK as a marker of squamous cell carcinoma led to a
correct prediction of NSCLC subtype in 21 of 23 resected cases.
Monica et al.35 reported the value of desmocollin-3 (DSC-3), as
a squamous marker, and TTF1 in predicting the histotype of 31
cytologic samples diagnosed as NSCLC-NOS. These two mark-
ers appear to be mutually exclusively expressed in squamous
and adenocarcinomas, respectively.
None of the markers is specific for a particular tumor
histotype. In consequence, there is an understandable and un-
avoidable error rate in the predicted histotype based on the IHC
staining profile. One large series of surgically resected NSCLC
showed 30% of adenocarcinomas and 37% of large cell carci-
nomas positive for p6316; another found 40% of large cell
carcinomas positive for TTF1.25 TTF1 positivity has been re-
ported in 5 to 21% of squamous cell carcinomas,30–32 but, in our
experience and that of others, TTF1 does not stain pulmonary
squamous cell carcinomas.25,27 Our data showed that although
some squamous and adenocarcinomas had a null, nonpredictive
immunophenotype, none showed the opposing, predictive im-
munophenotype when the biopsy sample was undifferentiated.
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No squamous cell carcinoma showed an adenocarcinoma im-
munophenotype and vice versa.
Some true large cell carcinomas had an immunopheno-
type that suggested either adenocarcinoma or squamous cell
carcinoma; an observation also made by others.35 Ultrastruc-
tural evidence of differentiation in large cell carcinomas is
also well recognized. This is commensurate with the hypoth-
esis that many large cell carcinomas may be dedifferentiated
squamous cell or adenocarcinomas, which retain their molec-
ular but lose their morphologic differentiation.
Immunohistochemistry profiles do not feature in the
diagnostic criteria for squamous cell or adenocarcinoma in
the current WHO classification.6 Marker profiles may be used
as supporting evidence for a particular histotype in the ab-
sence of morphologic evidence, but they do not confirm the
diagnosis. Care should be exercised in their use when report-
ing such cases. The authors’ practice is to continue to sign out
undifferentiated cases as NSCLC but add an appropriate
qualification of probably squamous cell or adenocarcinoma if
the IHC profile is predictive.
The treatment of advanced NSCLC has seen significant
progress in recent years with the emergence of a number of
agents that show differential efficacy or toxicity in certain
subtypes of NSCLC.4,5,36,37 In consequence, there is greater
pressure on pathologists to be more specific in their diagnosis
of small biopsy and cytology samples. A diagnosis of
NSCLC-NOS should be refined where at all possible but may
be unavoidable in a small proportion of cases, especially
where the diagnostic sample contains very little tumor. Our
results show that p63 and AB/PAS are the most efficient at
predicting squamous versus nonsquamous histology, which is
currently the relevant distinction to guide choice of some
newer treatments. By using a panel of markers such as
suggested in this study, the predictive nature of the refined
diagnosis needs to be borne in mind. There are no data to
suggest that, for example, a tumor classified as NSCLC,
probably squamous cell on the basis of IHC, would be
resistant to pemetrexed in the same way that a morphologi-
cally diagnosable case would likely be. Those clinical trials
that demonstrated differential efficacy or toxicity of an agent
were based on pathologic diagnoses from a multitude of
pathologists, using many sample types and variable methods
to reach a diagnosis. The emergence of such drugs indicates
the need for greater consideration of the accuracy and con-
sistency of pathologic diagnosis in future clinical trials. This
requires the use of standardized IHC-based histotyping and
central pathologic review.
Our predictive panel can improve the diagnostic algorithm
for NSCLC (Figure 2). NSCLC-NOS rates on small biopsy
samples will vary according to the skill, confidence, and bias of
individual pathologists. Published data suggest that 75% of
bronchial NSCLC samples may be subtyped using morphology
alone.9 Of the remaining 25% of samples, those lacking mor-
phologic differentiation, this study shows that 73% are given a
probable subtype, thus, typing is achieved in 75  (25 
0.73)  93% of all NSCLC cases. The accuracy of both
morphologic- and IHC-based predictive subtyping is 100%
(Figure 2). The exact concordance between morphologic- and
panel-predicted subtype in our prospective data suggests the use
of IHC in morphologically diagnosable cases could improve this
accuracy. In our NSCLC-NOS biopsy samples, inaccurately
attributed cases were all accounted for by large cell carcinomas
with a predictive immunophenotype. Overall, therefore, only 7%
of all NSCLC bronchial biopsy samples should remain without
a probable subtype after morphologic examination, IHC, and
mucin staining.
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